TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic StrokeFAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented Tethered Enzyme Technology (TET), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NSE-FAST® (Neuron Specific Enolase — Functional Activity Stroke Test), a rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke.
